Insights into the future of gastric acid suppression

@article{Devault2009InsightsIT,
  title={Insights into the future of gastric acid suppression},
  author={Kenneth R. Devault and Nicholas J. Talley},
  journal={Nature Reviews Gastroenterology \&Hepatology},
  year={2009},
  volume={6},
  pages={524-532}
}
The development of effective acid-suppression therapy (particularly PPIs) has revolutionized the treatment of acid-related diseases. Despite the overall effectiveness of these agents, they have some shortcomings, including a delayed onset of action, incomplete acid suppression in the majority of patients, and the need for ingestion before a meal to achieve maximal efficacy. Attempts to overcome these issues have included the development of isomeric PPIs (such as esomeprazole), alterations in… Expand
Pharmacological Approach to Gastric Acid Suppression: Past, Present, and Future
TLDR
Challenges persist in the therapy of acid related diseases, including management of patients who respond inadequately to PPI therapy, more effective gastroprotection, or more powerful antisecretory treatment for the eradication of Helicobacter pylori infection. Expand
A fruitful Discovery of proton pump inhibitors and its future
Acid related diseases like erosive eosophagitis, GERD and H.Pylori resistance are major future health-care concerns. In the past 50 years despite the dramatic success of pharmacological acidExpand
New Pharmacologic Approaches in Gastroesophageal Disease
TLDR
Improved outcomes can be achieved by fine-tuning treatment using currently available medications, based on their pharmacology and the patient’s disease manifestations; a careful consideration of the choice of drug, dose, and treatment regimen is crucial in the day-to-day management of GERD. Expand
Long-term Acid Suppression Therapy: Its Influence on Gastric Mucosa
TLDR
Gastric mucosal changes especially intestinal metaplasia is more common with PPI with fewer mucosalChanges when on H2RA and is not influenced by the presence of H. pylori, which indicates long-term acid suppressants are generally safe. Expand
Proton pump inhibitor-associated pneumonia: Not a breath of fresh air after all?
TLDR
The current literature shows a slight trend toward an association between PPI use and pneumonia and an increased risk with PPIs over H(2)RAs, but the findings are not consistent across all studies. Expand
Control of Intragastric pH and Its Relationship to Gastroesophageal Reflux Disease Outcomes
TLDR
This review summarizes and critically evaluates available evidence linking intragastric pH and GERD outcomes and concludes that well-designed, long-term outcome studies are still needed to elucidate the link among GERD symptoms, acid suppressive therapy, and 24-hour gastric pH profiles. Expand
Inhibiting the proton pump: mechanisms, benefits, harms, and questions
TLDR
Proton pump inhibitors are widely used in upper gastrointestinal diseases, including gastric and duodenal ulcers, eradication of Helicobacter pylori in combination with antibiotics, gastroesophageal reflux disease, Zollinger–Ellison syndrome, eosinophilic esophagitis, and prevention of non-steroidal anti-inflammatory drug-induced peptic ulceration. Expand
Helicobacter pylori Therapy in Children: A Focus on Proton Pump Inhibitors
TLDR
This article comprehensively review the literature on the clinical, pharmacologic and microbiologic properties of PPIs from a pediatric point of view, and provides some guidance regarding their potential role and limitations for H. pylori eradication in children. Expand
Association of Long-Term Proton Pump Inhibitor Therapy with Bone Fractures and Effects on Absorption of Calcium, Vitamin B12, Iron, and Magnesium
TLDR
Significant results of several studies support the conclusion that long-term adverse effects on these processes can have important clinical implications, and studies of the effects of chronic PPI use on absorption of VB12, iron, and magnesium are examined. Expand
Esomeprazole for the treatment of peptic ulcer bleeding
TLDR
Continuous high-dose intravenous treatment with esomeprazole decreases rebleeding, surgery, transfusion rates and hospital days in peptic ulcer bleeding. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 160 REFERENCES
Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
TLDR
A new class of acid suppressant, the potassium-competitive acid blockers (P-CABs), is undergoing clinical trials in GERD and other acid-related diseases and it is unlikely that cholecystokinin2 (CCK2, gastrin) receptor antagonists, a class in clinical trials, will be superior to H2RAs or PPIs. Expand
Acid Suppression Therapy: Where Do We Go from Here?
TLDR
Clinicians will continue to rely on PPIs to control acid secretion in GERD and other acid-related diseases and two novel drugs (namely ilaprazole and tenatoprazole) are being studied in humans. Expand
Pharmacology of proton pump inhibitors
TLDR
All PPIs give excellent healing of peptic ulcers and produce good results in reflux esophagitis and combined with antibiotics eradicate Helicobacter pylori. Expand
Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.
TLDR
The degree and rate of healing seem to be related to the reduction in oesophageal acid exposure and thus may correlate with the degree and duration of acid suppression over 24 hours obtained by the various treatments. Expand
A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease
TLDR
AZD0865 did not provide clinical benefit over esomeprazole 20 mg in the management of patients with NERD and was generally well tolerated although reversible elevations of liver transaminases occurred in some patients receiving the agent. Expand
Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.
TLDR
The combination of H2RA and PPI therapy reduced NAB only with the introduction of therapy, and there was no difference in acid suppression between PPI twice daily and P PI twice daily + H2 RA after 1 week of combination therapy. Expand
Appropriate acid suppression for the management of gastro-oesophageal reflux disease.
TLDR
Preliminary meta-analysis shows that the healing rate of erosive oesophagitis at 8 weeks by antisecretory agents is directly related to the duration of suppression of gastric acid secretion achieved over a 24-hour period. Expand
Review of immediate-release omeprazole for the treatment of gastric acid-related disorders
  • D. Castell
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2005
TLDR
The immediate-release formulation may provide a good treatment option for patients who require flexible dosing, quick onset of action and nocturnal gastric acid control, and seems to provide better night time control of gastric Acidity than that observed with conventional morning dosing of delayed-release proton pump inhibitors. Expand
Omeprazole Therapy Causes Malabsorption of Cyanocobalamin (Vitamin B12)
TLDR
The effect of omeprazole on cyanocobalamin absorption is analyzed, because neurologic disorders caused by cyanOCobalamin deficiency are often irreversible and can occur in the absence of any hematologic abnormalities. Expand
Importance of pH control in the management of GERD.
  • R. Hunt
  • Medicine
  • Archives of internal medicine
  • 1999
TLDR
The PPIs are significantly more effective than the H2RAs in achieving and sustaining an intragastric pH above 4.0 and the results of clinical trials performed with the PPIs indicate a faster rate of healing of erosive esophagitis and of symptom relief than treatment with H2 RAs. Expand
...
1
2
3
4
5
...